NDAORALTABLETPriority Review
Approved
Jul 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
6/8 — Strong
Priority Review
VOSEVI (sofosbuvir, velpatasvir, and voxilaprevir) by Gilead Sciences is rna replicase inhibitors [moa]. Approved for hepatitis c virus nucleotide analog ns5b polymerase inhibitor [epc]. First approved in 2017.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VOSEVI is a fixed-dose combination tablet containing sofosbuvir, velpatasvir, and voxilaprevir that treats hepatitis C virus (HCV) infection. It works through multiple mechanisms: sofosbuvir and velpatasvir inhibit viral RNA replication, while voxilaprevir inhibits the NS3/4A protease. This triple-agent approach provides pangenotypic HCV coverage with high cure rates across treatment-experienced and treatment-naive populations.
$46MPart D
PeakStable
11.3 years to LOEVOSEVI remains at peak revenue with modest Medicare utilization (1,771 Part D claims in 2023); team size suggests mature, consolidating portfolio requiring efficiency and optimization focus.
Mechanism of Action
RNA Replicase Inhibitors
Pharmacologic Class:
Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir in Subjects With Previous DAA Experience
Started May 2016
77 enrolled
Chronic Hepatitis C
Career Relevance
VOSEVI careers span R&D, regulatory, and quality disciplines reflecting a mature, marketed product where technical excellence and compliance are critical. The 263 linked roles indicate sustained but specialized team demand, suggesting opportunities in regulatory strategy, manufacturing optimization, and pharmacovigilance rather than broad commercial expansion.
Director
Worked on VOSEVI at Gilead Sciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.